Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

COLORECTAL CANCER IN 2021

Optimizing immunotherapy for colorectal cancer

Important colorectal cancer (CRC) studies in 2021, including a new standard of care for first-line treatment of MSI-H–dMMR metastatic CRC, single-cell and spatial analysis of primary tumours and investigations of diet in preclinical models of cancer initiation, have provided novel insights into the CRC immune microenvironment.

Key advances

  • Pembrolizumab (an anti-PD1 monoclonal antibody) has been established as the new standard of care for first-line treatment of metastatic microsatellite-high–mismatch repair-deficient colorectal cancer4.

  • Comprehensive single-cell and spatial analyses of patient samples have identified distinct multicellular immune modulatory hubs in mismatch repair-deficient and mismatch repair-proficient primary colon tumours9.

  • High-fat diet can cause microbiome-dependent downregulation of MHC class II expression on LGR5+ intestinal stem cells in mice, in turn enabling immune evasion and promoting intestinal tumorigenesis10.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Modulating the local and systemic immune microenvironment of colorectal cancer.

References

  1. Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 16, 361–375 (2019).

    Article  Google Scholar 

  2. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

    CAS  Article  Google Scholar 

  3. Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).

    CAS  Article  Google Scholar 

  4. André, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020).

    Article  Google Scholar 

  5. Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773–779 (2018).

    CAS  Article  Google Scholar 

  6. Lenz, H.-J. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 Study. J. Clin. Oncol. https://doi.org/10.1200/JCO.21.01015 (2021).

    Article  PubMed  Google Scholar 

  7. Ganesh, K. & Massagué, J. Targeting metastatic cancer. Nat. Med. 27, 34–44 (2021).

    CAS  Article  Google Scholar 

  8. Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).

    CAS  Article  Google Scholar 

  9. Pelka, K. et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell 184, 4734–4752 (2021).

    CAS  Article  Google Scholar 

  10. Beyaz, S. et al. Dietary suppression of MHC class II expression in intestinal epithelial cells enhances intestinal tumorigenesis. Cell Stem Cell 28, 1922–1935 (2021).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

K.G. is supported by NIH grants K08 CA230213, U2C CA233284 and P30 CA 008748, a Damon Runyon Clinical Investigator Award, Burroughs Wellcome Career Award for Medical Scientists, AACR NextGen Grant for Transformative Cancer Research, Josie Robertson Investigator Award and a Stand Up To Cancer Convergence Award.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karuna Ganesh.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ganesh, K. Optimizing immunotherapy for colorectal cancer. Nat Rev Gastroenterol Hepatol 19, 93–94 (2022). https://doi.org/10.1038/s41575-021-00569-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-021-00569-4

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing